The Molecular and Cellular Biology of HER2/neu Gene Amplification/Overexpression and the Clinical Development of Herceptin (Trastuzumab) Therapy for Breast Cancer (original) (raw)
Slamon, D.J. Oncogenes and human malignancy, pp 226–229. In: Cline, M.J. Moderator. Oncogenes: Implications for the diagnosis and treatment of cancer. Ann Int Med 101:223–233, 1984. Google Scholar
Shih C, Padhy L, Murray M, et al.,Transforming genes of carcinomas and neuroblastomas introduced into muonse fibroblasts. Nature 1981; 260: 261264. Google Scholar
Coussens L, Yang-Feng TL, Liao YC, et al.,Tyrosine kinase receptor with extensive homology fo EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132–1139. Google Scholar
King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb-B-2related gene in human mammary carcinoma. Science 1985; 229: 974–6. ArticlePubMedCAS Google Scholar
Carraway K, Cantley L. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994; 78: 5–8. ArticlePubMedCAS Google Scholar
Sliwkowski M, Schaefer G, Akita R, et al., Coexpression of erB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269: 15661–14665. Google Scholar
Plowman G, Culouscou J-M, Whitney G, et al., Ligand-specific activiation of HER4/p180erB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993; 90: 1746–1750. ArticlePubMedCAS Google Scholar
Reese DM and Slamon DJ. HER-2/neu Signal Transduction in Human Breast and Ovarian Cancer. Stem Cells 1997; 15: 1–8. ArticlePubMedCAS Google Scholar
Wen D, Suggs SV, Karunagaran D, et al. Structural and functional aspects of the multiplicity of neu differentiation factors. Molecular and Cellualr Biology 14: 1909–1919, 1994. CAS Google Scholar
Wen D, Peles E, Cupples R, et al. Neu differentiation factor: a transmembrane glycoprotein containing and EGF domain and an immunoglobulin homology unit. Cell 69: 559–572, 1992. ArticlePubMedCAS Google Scholar
Falls, DL, Rosen KM, Corfas G, et al. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 72: 801, 1993. ArticlePubMedCAS Google Scholar
Marchionni M, Goodearl A, Chen M, et al. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362: 312, 1993. ArticlePubMedCAS Google Scholar
Peles E, Ben-Levy R, Tzahor E, et al. Cell-type specific interaction of neu differentiation factor (NDF/heregulin) with neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12: 961–971, 1993. PubMedCAS Google Scholar
Slamon DJ, Clark GM, Wong SG, et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182. ArticlePubMedCAS Google Scholar
Slamon DJ, Godolphin W, Jones LA, et al., Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712. ArticlePubMedCAS Google Scholar
Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936–1942, 1993. PubMedCAS Google Scholar
Press MF, Hung G, Godolphin W, et al., Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771–2777. PubMedCAS Google Scholar
Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10: 1044–1048, 1992. PubMedCAS Google Scholar
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D, for the Toronto Breast Cancer Study Group: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16: 1340–1349, 1998. PubMedCAS Google Scholar
Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 42854289, 1992. Google Scholar
Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63–72, 1996. PubMedCAS Google Scholar
Roche and Ingle, Increased HER2 with U.S. FDA-Approved Antibody J Clin Oncol 17: 434–435, 1999(letter). Google Scholar
Diane Maia, Immunohistochemical Assays for HER2 Overexpression J Clin Oncol 17: 434, 1999. Google Scholar
Pegram M, Lipton A, Hayes D, et al: Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER-2/neu Monoclonal Antibody Plus Cisplatin in Patients With HER-2/neu-Overexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J Clin Oncol 16: 2659–2671, 1998. PubMedCAS Google Scholar
Pegram MD, Pauletti G, and Slamon DJ., HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res and Treat 1998, 52 (1–3): 65–77. ArticleCAS Google Scholar
Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-pl85HER2 monoclonal antibodies. Cancer Immunol Immunother 37: 255–263, 1993. ArticlePubMedCAS Google Scholar
Herceptin (Trastuzumab) anti-HER2 monoclonal antibody: product package insert, Genentech, Inc. South San Francisco, CA, copyright September, 1998. Google Scholar
Pegram MD, Baly D, Wirth C, et al., Antibody dependent cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of a humanized anti-HER2 antibody. Proc Am Assoc Cancer Res 1997;3 8:602(abstract). Google Scholar
Pietras RJ, Pegram MD, Finn RS, et al: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17: 2235–2249, 1998. ArticlePubMedCAS Google Scholar
Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829–1838, 1994. PubMedCAS Google Scholar
Aboud-Pirak E, Hurwitz E, Pirak ME, et al: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80: 1605–1611, 1988. ArticlePubMedCAS Google Scholar
Pegram M, Hsu S, Lewis G, et al., Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241–2251, 1999. ArticlePubMedCAS Google Scholar
Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744, 1996. PubMedCAS Google Scholar
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G, Slamon D: Efficacy and Safety of Herceptin (Humanized Anti-HER2 Antibody) as a Single Agent in 222 Women with HER2 Overexpression who Relapsed Following Chemotherapy for Metastatic Breast Cancer. Proc Am Soc Clin Oncol 17: 376, 1998. Google Scholar
Vogel CL, Cobleigh MA, Tripathy D, et al., Efficacy and safety of Herceptin (Trastuzumab, humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC). Breast Cancer Res and Treat 1998; 50: 232a. Google Scholar
Pegram M, Lipton A, Hayes D, et al: Phase II Study of Receptor-Enhanced Chemosensitivity Using Recombinant Humanized Anti-p185HER-2/neu Monoclonal Antibody Plus Cisplatin in Patients With HER-2/neuOverexpressing Metastatic Breast Cancer Refractory to Chemotherapy Treatment. J Clin Oncol 16: 2659–2671, 1998. PubMedCAS Google Scholar
Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of Herceptin (Humanized anti-HER-2 Antibody) to First Line Chemotherapy for HER2 Overexpressing Metastatic Breast Cancer (HER2+MBC) Markedly Increases Anticancer Activity: A Randomized, Multinational Controlled Phase III Trial. Proc Am Soc Clin Oncol 17: 377, 1998. Google Scholar
Norton L, Slamon D, Leyland-JHones B, et al., Overall Survival (OS) Advantage to Simultaneous chemotherapy (Crx) Plus the Humanized AntiHER2 Monoclonal Antibody Herceptin (H) in HER2-Overexpressing (HER2+) Metastatic Breast Cancer (MBC). Prc Am Soc Clin Oncol 1999; 18: 483 (abstract). Google Scholar
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson C: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Medicine 330: 1260–1266, 1994. ArticleCAS Google Scholar
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer. J Natl Cancer Inst 90: 1346–1360, 1998. ArticlePubMedCAS Google Scholar
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor-Negative Breast Cancer. J Natl Cancer Inst 90: 1361–1370, 1998. ArticlePubMedCAS Google Scholar